Details of the Drug

General Information of Drug (ID: DMRHGI9)

Drug Name
Cisplatin
Synonyms
Abiplatin; Biocisplatinum; Briplatin; Cismaplat; Cisplatine; Cisplatino; Cisplatinum; Cisplatyl; Citoplationo; Lederplatin; Neoplatin; Plastin; Platamine; Platidiam; Platinoxan; Randa; Cis-DDP; Cis-Diamminedichloroplatinum; Peyrone's chloride; Peyrone's salt; Cis-Dichlorodiammineplatinum(II); Cis-[PtCl2(NH3)2]; Cis-diamminedichloridoplatinum(II); Trans-diamminedichloridoplatinum(II); (SP-4-1)-diamminedichloridoplatinum; (SP-4-1)-diamminedichloroplatinum; (SP-4-2)-diamminedichloridoplatinum; (SP-4-2)-diamminedichloroplatinum; Cisplatin (Chemotherapy)
Indication
Disease Entry ICD 11 Status REF
Adenocarcinoma 2D40 Approved [1]
Anterior urethra cancer N.A. Approved [1]
Carcinoma 2A00-2F9Z Approved [1]
Central nervous system neoplasm N.A. Approved [1]
Epithelial ovarian cancer 2B5D Approved [1]
Epithelioid mesothelioma 2F10 Approved [1]
Esophageal squamous cell carcinoma 2E60.1 Approved [1]
Extragonadal germ cell tumor N.A. Approved [1]
Gastric intestinal type adenocarcinoma N.A. Approved [1]
Gastroesophageal junction adenocarcinoma 2B71 Approved [1]
Lung cancer 2C25.0 Approved [1]
Non-small-cell lung cancer 2C25.Y Approved [1]
Plasma cell myeloma 2A83.1 Approved [1]
Posterior urethra cancer N.A. Approved [1]
Primary peritoneal carcinoma N.A. Approved [1]
Primitive neuroectodermal tumor N.A. Approved [1]
Sarcomatoid mesothelioma N.A. Approved [1]
Small-cell lung cancer 2C25.Y Approved [1]
Solid tumour/cancer 2A00-2F9Z Approved [2]
Testicular germ cell tumor N.A. Approved [1]
Urinary bladder neoplasm N.A. Approved [1]
Osteosarcoma 2B51 Phase 2 [3]
Gastric cancer 2B72 Investigative [1]
⏷ Show the Full List of Indication(s)
Therapeutic Class
Anticancer Agents
Drug Type
Small molecular drug
Structure
3D MOL is unavailable 2D MOL
#Ro5 Violations (Lipinski):
0		 Molecular Weight 300.05
Logarithm of the Partition Coefficient Not Available
Rotatable Bond Count 0
Hydrogen Bond Donor Count 2
Hydrogen Bond Acceptor Count 2
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [4]
Elimination
2.3% of drug is excreted from urine in the unchanged form [4]
Half-life
The concentration or amount of drug in body reduced by one-half in 30 minutes (platinum in plasma), and more than 5 days (complexes between albuminutes and the platinum) [5]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 4.74882 micromolar/kg/day [6]
Water Solubility
The ability of drug to dissolve in water is measured as 2.53 mg/mL [4]
Adverse Drug Reaction (ADR)
ADR Term Variation Related DOT DOT ID REF
Cell-mediated cytotoxicity Not Available PTK6 OT7NWIQ0 [7]
Electrolyte imbalance Not Available BGLAP OTK1YLWQ [7]
Electrolyte imbalance Not Available PTH1R OTQF5ZAK [7]
Hypersensitivity Not Available YBT1 OTPQCBKA [7]
Nephropathy toxic Not Available HEXA OT48T897 [7]
Neutropenia rs4627050 PTPN5 OT2H1KDK [8]
Neutropenia rs2406342 ZNF236 OTXXMGJA [8]
Ototoxicity rs2075252 LRP2 OTZ6W681 [9]
Renal failure acute Not Available NCOA1 OTLIUJQD [7]
Renal failure acute Not Available ACOX1 OTM0A0DY [7]
Renal failure acute Not Available RXRA OTP1TBDM [7]
⏷ Show the Full List of 11 ADR Information of This Drug
Chemical Identifiers
Formula
Cl2H6N2Pt
IUPAC Name
azane;dichloroplatinum
Canonical SMILES
N.N.Cl[Pt]Cl
InChI
InChI=1S/2ClH.2H3N.Pt/h2*1H;2*1H3;/q;;;;+2/p-2
InChIKey
LXZZYRPGZAFOLE-UHFFFAOYSA-L
Cross-matching ID
PubChem CID
5702198
CAS Number
15663-27-1
DrugBank ID
DB00515
TTD ID
D0U5HU
VARIDT ID
DR00291
INTEDE ID
DR0332
ACDINA ID
D00950
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Human Deoxyribonucleic acid (hDNA) TTUTN1I NOUNIPROTAC Modulator [10]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
High affinity copper uptake protein 1 (SLC31A1) DTP8L4F COPT1_HUMAN Substrate [11]
Copper-transporting ATPase 2 (ATP7B) DT206GF ATP7B_HUMAN Substrate [12]
Multidrug resistance-associated protein 6 (ABCC6) DT582KR MRP6_HUMAN Substrate [13]
Probable low affinity copper uptake protein 2 (SLC31A2) DT8Q56F COPT2_HUMAN Substrate [14]
Multidrug resistance-associated protein 2 (ABCC2) DTFI42L MRP2_HUMAN Substrate [15]
Organic cation transporter 1 (SLC22A1) DTT79CX S22A1_HUMAN Substrate [16]
Multidrug resistance-associated protein 1 (ABCC1) DTSYQGK MRP1_HUMAN Substrate [17]
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [18]
Organic cation transporter 2 (SLC22A2) DT9IDPW S22A2_HUMAN Substrate [19]
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [20]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 2E1 (CYP2E1) DEVDYN7 CP2E1_HUMAN Substrate [21]
Glutathione S-transferase alpha-1 (GSTA1) DE4ZHS1 GSTA1_HUMAN Substrate [22]
Quinone reductase 1 (NQO1) DENP5RY NQO1_HUMAN Substrate [23]
Glutathione S-transferase pi (GSTP1) DEK6079 GSTP1_HUMAN Substrate [24]
Metallothionein-1A (MT1A) DE5ME8A MT1A_HUMAN Substrate [25]
Myeloperoxidase (MPO) DEA3U9Y PERM_HUMAN Substrate [26]
Metallothionein-2A (MT2A) DEFKGT7 MT2_HUMAN Substrate [25]
Glutathione S-transferase mu-1 (GSTM1) DEYZEJA GSTM1_HUMAN Substrate [24]
Superoxide dismutase 1 (SOD1) DEUTDON SODC_HUMAN Substrate [23]
Glutathione S-transferase theta-1 (GSTT1) DE3PKUG GSTT1_HUMAN Substrate [24]
Glutathione S-transferase alpha-4 (GSTA4) DEH7XYP GSTA4_HUMAN Substrate [27]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
(3R)-3-hydroxyacyl-CoA dehydrogenase (HSD17B8) OTX1DWEF DHB8_HUMAN Gene/Protein Processing [28]
(Lyso)-N-acylphosphatidylethanolamine lipase (ABHD4) OTQK3M9X ABHD4_HUMAN Gene/Protein Processing [29]
1,25-dihydroxyvitamin D(3) 24-hydroxylase, mitochondrial (CYP24A1) OTG2T749 CP24A_HUMAN Gene/Protein Processing [28]
1,4-alpha-glucan-branching enzyme (GBE1) OTK2N05B GLGB_HUMAN Gene/Protein Processing [30]
1-acyl-sn-glycerol-3-phosphate acyltransferase beta (AGPAT2) OT5I4Y9K PLCB_HUMAN Gene/Protein Processing [30]
1-acylglycerol-3-phosphate O-acyltransferase ABHD5 (ABHD5) OTY829Z3 ABHD5_HUMAN Gene/Protein Processing [31]
1-acylglycerol-3-phosphate O-acyltransferase PNPLA3 (PNPLA3) OTR4990X PLPL3_HUMAN Gene/Protein Processing [28]
1-aminocyclopropane-1-carboxylate synthase-like protein 1 (ACCS) OTHIHI9D 1A1L1_HUMAN Gene/Protein Processing [31]
1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase beta-2 (PLCB2) OTPAHDGO PLCB2_HUMAN Gene/Protein Processing [30]
1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase beta-4 (PLCB4) OTPA0QHW PLCB4_HUMAN Gene/Protein Processing [28]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Cisplatin (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Remdesivir DMBFZ6L Moderate Decreased renal excretion of Cisplatin caused by Remdesivir mediated nephrotoxicity. 1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019] [32]
Inotersen DMJ93CT Major Increased risk of nephrotoxicity by the combination of Cisplatin and Inotersen. Amyloidosis [5D00] [33]
Dronedarone DMA8FS5 Major Increased risk of ventricular arrhythmias by the combination of Cisplatin and Dronedarone. Angina pectoris [BA40] [34]
Roflumilast DMPGHY8 Moderate Additive immunosuppressive effects by the combination of Cisplatin and Roflumilast. Asthma [CA23] [33]
Ofloxacin DM0VQN3 Minor Decreased absorption of Cisplatin due to intestinal mucosa variation caused by Ofloxacin. Bacterial infection [1A00-1C4Z] [35]
Ciprofloxacin XR DM2NLS9 Minor Decreased absorption of Cisplatin due to intestinal mucosa variation caused by Ciprofloxacin XR. Bacterial infection [1A00-1C4Z] [35]
Trovafloxacin DM6AN32 Minor Decreased absorption of Cisplatin due to intestinal mucosa variation caused by Trovafloxacin. Bacterial infection [1A00-1C4Z] [35]
Sparfloxacin DMB4HCT Minor Decreased absorption of Cisplatin due to intestinal mucosa variation caused by Sparfloxacin. Bacterial infection [1A00-1C4Z] [35]
Gemifloxacin DMHT34O Minor Decreased absorption of Cisplatin due to intestinal mucosa variation caused by Gemifloxacin. Bacterial infection [1A00-1C4Z] [35]
Norfloxacin DMIZ6W2 Minor Decreased absorption of Cisplatin due to intestinal mucosa variation caused by Norfloxacin. Bacterial infection [1A00-1C4Z] [35]
ABT-492 DMJFD2I Minor Decreased absorption of Cisplatin due to intestinal mucosa variation caused by ABT-492. Bacterial infection [1A00-1C4Z] [35]
Rabeprazole DMMZXIW Moderate Increased risk of hypomagnesemia by the combination of Cisplatin and Rabeprazole. Bacterial infection [1A00-1C4Z] [36]
Levofloxacin DMS60RB Minor Decreased absorption of Cisplatin due to intestinal mucosa variation caused by Levofloxacin. Bacterial infection [1A00-1C4Z] [35]
Lomefloxacin DMVRH9C Minor Decreased absorption of Cisplatin due to intestinal mucosa variation caused by Lomefloxacin. Bacterial infection [1A00-1C4Z] [35]
Etidronic acid DM1XHYJ Moderate Increased risk of nephrotoxicity by the combination of Cisplatin and Etidronic acid. Bone paget disease [FB85] [37]
Iodipamide DMXIQYS Major Increased risk of nephrotoxicity by the combination of Cisplatin and Iodipamide. Cholelithiasis [DC11] [38]
Methoxyflurane DML0RAE Moderate Increased risk of nephrotoxicity by the combination of Cisplatin and Methoxyflurane. Corneal disease [9A76-9A78] [33]
Ethacrynic acid DM60QMR Moderate Increased risk of ototoxicity by the combination of Cisplatin and Ethacrynic acid. Essential hypertension [BA00] [39]
Amphotericin B DMTAJQE Moderate Increased risk of nephrotoxicity by the combination of Cisplatin and Amphotericin B. Fungal infection [1F29-1F2F] [32]
Dexlansoprazole DM1DBV5 Moderate Increased risk of hypomagnesemia by the combination of Cisplatin and Dexlansoprazole. Gastro-oesophageal reflux disease [DA22] [36]
Furosemide DMMQ8ZG Moderate Increased risk of ototoxicity by the combination of Cisplatin and Furosemide. Heart failure [BD10-BD1Z] [40]
Bumetanide DMRV7H0 Moderate Increased risk of ototoxicity by the combination of Cisplatin and Bumetanide. Heart failure [BD10-BD1Z] [40]
Brentuximab vedotin DMWLC57 Moderate Increased risk of peripheral neuropathy by the combination of Cisplatin and Brentuximab vedotin. Hodgkin lymphoma [2B30] [41]
Zalcitabine DMH7MUV Moderate Increased risk of peripheral neuropathy by the combination of Cisplatin and Zalcitabine. Human immunodeficiency virus disease [1C60-1C62] [42]
Teriflunomide DMQ2FKJ Major Additive immunosuppressive effects by the combination of Cisplatin and Teriflunomide. Hyper-lipoproteinaemia [5C80] [43]
Etelcalcetide DMHP9BL Major Increased risk of hypocalcemia by the combination of Cisplatin and Etelcalcetide. Hyper-parathyroidism [5A51] [33]
Diazoxide DML1538 Minor Increased risk of nephrotoxicity by the combination of Cisplatin and Diazoxide. Hypertension [BA00-BA04] [44]
Givosiran DM5PFIJ Moderate Increased risk of nephrotoxicity by the combination of Cisplatin and Givosiran. Inborn porphyrin/heme metabolism error [5C58] [32]
Balsalazide DM7I1T9 Moderate Increased risk of nephrotoxicity by the combination of Cisplatin and Balsalazide. Indeterminate colitis [DD72] [45]
Methotrexate DM2TEOL Moderate Increased risk of nephrotoxicity by the combination of Cisplatin and Methotrexate. Leukaemia [2A60-2B33] [32]
Ibandronate DM0QZBN Moderate Increased risk of nephrotoxicity by the combination of Cisplatin and Ibandronate. Low bone mass disorder [FB83] [46]
Denosumab DMNI0KO Moderate Additive immunosuppressive effects by the combination of Cisplatin and Denosumab. Low bone mass disorder [FB83] [47]
Arsenic trioxide DM61TA4 Major Increased risk of ventricular arrhythmias by the combination of Cisplatin and Arsenic trioxide. Mature B-cell lymphoma [2A85] [48]
Clofarabine DMCVJ86 Moderate Increased risk of nephrotoxicity by the combination of Cisplatin and Clofarabine. Mature B-cell lymphoma [2A85] [49]
Exjade DMHPRWG Major Increased risk of nephrotoxicity by the combination of Cisplatin and Exjade. Mineral absorption/transport disorder [5C64] [50]
Thalidomide DM70BU5 Major Additive thrombogenic effects by the combination of Cisplatin and Thalidomide. Multiple myeloma [2A83] [51]
Tecfidera DM2OVDT Moderate Additive immunosuppressive effects by the combination of Cisplatin and Tecfidera. Multiple sclerosis [8A40] [52]
Siponimod DM2R86O Major Additive immunosuppressive effects by the combination of Cisplatin and Siponimod. Multiple sclerosis [8A40] [32]
Fingolimod DM5JVAN Major Additive immunosuppressive effects by the combination of Cisplatin and Fingolimod. Multiple sclerosis [8A40] [53]
Ocrelizumab DMEZ2KH Moderate Additive immunosuppressive effects by the combination of Cisplatin and Ocrelizumab. Multiple sclerosis [8A40] [54]
Ozanimod DMT6AM2 Major Additive immunosuppressive effects by the combination of Cisplatin and Ozanimod. Multiple sclerosis [8A40] [33]
Omacetaxine mepesuccinate DMPU2WX Moderate Additive myelosuppressive effects by the combination of Cisplatin and Omacetaxine mepesuccinate. Myeloproliferative neoplasm [2A20] [55]
Levomethadyl Acetate DM06HG5 Major Increased risk of ventricular arrhythmias by the combination of Cisplatin and Levomethadyl Acetate. Opioid use disorder [6C43] [56]
Esomeprazole DM7BN0X Moderate Increased risk of hypomagnesemia by the combination of Cisplatin and Esomeprazole. Peptic ulcer [DA61] [36]
Pemetrexed DMMX2E6 Moderate Decreased renal excretion of Cisplatin caused by Pemetrexed mediated nephrotoxicity. Pleural mesothelioma [2C26] [57]
Fluphenazine DMIT8LX Moderate Increased risk of ventricular arrhythmias by the combination of Cisplatin and Fluphenazine. Psychotic disorder [6A20-6A25] [32]
Everolimus DM8X2EH Major Increased risk of nephrotoxicity by the combination of Cisplatin and Everolimus. Renal cell carcinoma [2C90] [58]
Temsirolimus DMS104F Major Increased risk of nephrotoxicity by the combination of Cisplatin and Temsirolimus. Renal cell carcinoma [2C90] [58]
Gatifloxacin DMSL679 Minor Decreased absorption of Cisplatin due to intestinal mucosa variation caused by Gatifloxacin. Respiratory infection [CA07-CA4Z] [35]
Canakinumab DM8HLO5 Moderate Additive immunosuppressive effects by the combination of Cisplatin and Canakinumab. Rheumatoid arthritis [FA20] [59]
Rilonacept DMGLUQS Moderate Additive immunosuppressive effects by the combination of Cisplatin and Rilonacept. Rheumatoid arthritis [FA20] [59]
Golimumab DMHZV7X Major Additive immunosuppressive effects by the combination of Cisplatin and Golimumab. Rheumatoid arthritis [FA20] [60]
Sulfasalazine DMICA9H Moderate Increased risk of nephrotoxicity by the combination of Cisplatin and Sulfasalazine. Rheumatoid arthritis [FA20] [45]
Leflunomide DMR8ONJ Major Additive myelosuppressive effects by the combination of Cisplatin and Leflunomide. Rheumatoid arthritis [FA20] [43]
Thioridazine DM35M8J Moderate Increased risk of ventricular arrhythmias by the combination of Cisplatin and Thioridazine. Schizophrenia [6A20] [32]
Paliperidone DM7NPJS Moderate Increased risk of ventricular arrhythmias by the combination of Cisplatin and Paliperidone. Schizophrenia [6A20] [32]
Trifluoperazine DMKBYWI Moderate Increased risk of ventricular arrhythmias by the combination of Cisplatin and Trifluoperazine. Schizophrenia [6A20] [32]
Risperidone DMN6DXL Moderate Increased risk of ventricular arrhythmias by the combination of Cisplatin and Risperidone. Schizophrenia [6A20] [32]
Amisulpride DMSJVAM Moderate Increased risk of ventricular arrhythmias by the combination of Cisplatin and Amisulpride. Schizophrenia [6A20] [32]
Pimozide DMW83TP Major Increased risk of ventricular arrhythmias by the combination of Cisplatin and Pimozide. Schizophrenia [6A20] [61]
Anthrax vaccine DM9GSWY Moderate Antagonize the effect of Cisplatin when combined with Anthrax vaccine. Sepsis [1G40-1G41] [62]
Sirolimus DMGW1ID Major Increased risk of nephrotoxicity by the combination of Cisplatin and Sirolimus. Transplant rejection [NE84] [58]
Azathioprine DMMZSXQ Moderate Additive immunosuppressive effects by the combination of Cisplatin and Azathioprine. Transplant rejection [NE84] [32]
Tacrolimus DMZ7XNQ Major Increased risk of nephrotoxicity by the combination of Cisplatin and Tacrolimus. Transplant rejection [NE84] [58]
Olsalazine DMZW9HA Moderate Increased risk of nephrotoxicity by the combination of Cisplatin and Olsalazine. Ulcerative colitis [DD71] [45]
Cinoxacin DM4EWNS Minor Decreased absorption of Cisplatin due to intestinal mucosa variation caused by Cinoxacin. Urinary tract infection [GC08] [35]
Nalidixic acid DMRM0JV Minor Decreased absorption of Cisplatin due to intestinal mucosa variation caused by Nalidixic acid. Urinary tract infection [GC08] [35]
Amiodarone DMUTEX3 Major Increased risk of ventricular arrhythmias by the combination of Cisplatin and Amiodarone. Ventricular tachyarrhythmia [BC71] [63]
Ganciclovir DM1MBYQ Moderate Increased risk of nephrotoxicity by the combination of Cisplatin and Ganciclovir. Virus infection [1A24-1D9Z] [32]
Valaciclovir DMHKS94 Moderate Increased risk of nephrotoxicity by the combination of Cisplatin and Valaciclovir. Virus infection [1A24-1D9Z] [33]
Valganciclovir DMS2IUH Moderate Additive myelosuppressive effects by the combination of Cisplatin and Valganciclovir. Virus infection [1A24-1D9Z] [32]
⏷ Show the Full List of 71 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Mannitol E00103 6251 Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
Sodium chloride E00077 5234 Diluent; Tonicity agent
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Cisplatin 10mg/vial injectable 10mg/vial Injectable Injection
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 Cisplatin FDA Label
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5343).
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 BDDCS applied to over 900 drugs
5 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
6 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
7 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
8 Genome-wide association study of chemotherapeutic agent-induced severe neutropenia/leucopenia for patients in Biobank Japan. Cancer Sci. 2013 Aug;104(8):1074-82. doi: 10.1111/cas.12186. Epub 2013 Jun 10.
9 Megalin genetic polymorphisms and individual sensitivity to the ototoxic effect of cisplatin. Pharmacogenomics J. 2008 Feb;8(1):23-8. doi: 10.1038/sj.tpj.6500455. Epub 2007 Apr 24.
10 Cisplatin and DNA repair in cancer chemotherapy.Trends Biochem Sci.1995 Oct;20(10):435-9.
11 Overcoming platinum drug resistance with copper-lowering agents. Anticancer Res. 2013 Oct;33(10):4157-61.
12 Effect of cisplatin on the transport activity of PII-type ATPases. Metallomics. 2017 Jul 19;9(7):960-968.
13 Characterization of the drug resistance and transport properties of multidrug resistance protein 6 (MRP6, ABCC6). Cancer Res. 2002 Nov 1;62(21):6172-7.
14 Copper transporter 2 regulates endocytosis and controls tumor growth and sensitivity to cisplatin in vivo. Mol Pharmacol. 2011 Jan;79(1):157-66.
15 Lentivirus-mediated RNAi silencing targeting ABCC2 increasing the sensitivity of a human nasopharyngeal carcinoma cell line against cisplatin. J Transl Med. 2008 Oct 4;6:55.
16 Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family). J Pharmacol Exp Ther. 2006 Nov;319(2):879-86.
17 Hammerhead ribozyme against gamma-glutamylcysteine synthetase sensitizes human colonic cancer cells to cisplatin by down-regulating both the glutathione synthesis and the expression of multidrug resistance proteins. Cancer Gene Ther. 2001 Oct;8(10):803-14.
18 Inhibiting the function of ABCB1 and ABCG2 by the EGFR tyrosine kinase inhibitor AG1478. Biochem Pharmacol. 2009 Mar 1;77(5):781-93.
19 Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 2. Am J Pathol. 2005 Dec;167(6):1477-84.
20 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
21 Cytochrome P450 2E1 null mice provide novel protection against cisplatin-induced nephrotoxicity and apoptosis. Kidney Int. 2003 May;63(5):1687-96.
22 Role of glutathione S-transferase P1-1 in the cellular detoxification of cisplatin. Mol Cancer Ther. 2008 Oct;7(10):3247-55.
23 PharmGKB: A worldwide resource for pharmacogenomic information. Wiley Interdiscip Rev Syst Biol Med. 2018 Jul;10(4):e1417. (ID: PA150642262)
24 Glutathione S-transferase genetic polymorphisms and individual sensitivity to the ototoxic effect of cisplatin. Anticancer Drugs. 2000 Sep;11(8):639-43.
25 Role of metallothionein in cisplatin sensitivity of germ-cell tumours. Int J Cancer. 2000 Mar 15;85(6):777-81.
26 Cisplatin reduces Brucella melitensis-infected cell number by inducing apoptosis, oxidant and pro-inflammatory cytokine production. Res Vet Sci. 2010 Apr;88(2):218-26.
27 GSTA4 mediates reduction of cisplatin ototoxicity in female mice. Nat Commun. 2019 Sep 12;10(1):4150.
28 Activation of AIFM2 enhances apoptosis of human lung cancer cells undergoing toxicological stress. Toxicol Lett. 2016 Sep 6;258:227-236.
29 Characterisation of cisplatin-induced transcriptomics responses in primary mouse hepatocytes, HepG2 cells and mouse embryonic stem cells shows conservation of regulating transcription factor networks. Mutagenesis. 2014 Jan;29(1):17-26.
30 Low doses of cisplatin induce gene alterations, cell cycle arrest, and apoptosis in human promyelocytic leukemia cells. Biomark Insights. 2016 Aug 24;11:113-21.
31 Acute hypersensitivity of pluripotent testicular cancer-derived embryonal carcinoma to low-dose 5-aza deoxycytidine is associated with global DNA Damage-associated p53 activation, anti-pluripotency and DNA demethylation. PLoS One. 2012;7(12):e53003. doi: 10.1371/journal.pone.0053003. Epub 2012 Dec 27.
32 Cerner Multum, Inc. "Australian Product Information.".
33 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
34 Product Information. Multaq (dronedarone). sanofi-aventis , Bridgewater, NJ.
35 Johnson EJ, MacGowan AP, Potter MN, et al "Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy." J Antimicrob Chemother 25 (1990): 837-42. [PMID: 2373666]
36 FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Low magnesium levels can be associated with long-term use of proton pump inhibitor drugs (PPIs).".
37 Chang JT, Green L, Beitz J "Renal failure with the use of zoledronic acid." N Engl J Med 349 (2003): 1676-9 discussion 1676-9. [PMID: 14573746]
38 Wong GT, Lee EY, Irwin MG. Contrast induced nephropathy in vascular surgery.?Br J Anaesth. 2016;117 Suppl 2:ii63-ii73. [PMID: 27566809]
39 Product Information. Edecrin (ethacrynic acid). Merck &amp Co, Inc, West Point, PA.
40 Komune S, Snow JB "Potentiating effects of cisplatin and ethacrynic acid in ototoxicity." Arch Otolaryngol 107 (1981): 594-7. [PMID: 7197152]
41 Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201. [PMID: 7756727]
42 Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6. [PMID: 219931]
43 Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.
44 Markman M, Trump DL "Nephrotoxicity with cisplatin and antihypertensive medications." Ann Intern Med 96 (1982): 257. [PMID: 7199267]
45 Novis BH, Korzets Z, Chen P, Bernheim J "Nephrotic syndrome after treatment with 5-aminosalicylic acid." Br Med J (Clin Res Ed) 296 (1988): 1442. [PMID: 3132281]
46 Banerjee D, Asif A, Striker L, Preston RA, Bourgoignie JJ, Roth D "Short-term, high-dose pamidronate-induced acute tubular necrosis: The postulated mechanisms of bisphosphonate nephrotoxicity." Am J Kidney Dis 41 (2003): E18. [PMID: 12778436]
47 Product Information. Prolia (denosumab). Amgen USA, Thousand Oaks, CA.
48 Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
49 Product Information. Clolar (clofarabine). sanofi-aventis, Bridgewater, NJ.
50 Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
51 Bennett CL, Nebeker JR, Samore MH, et al "The Research on Adverse Drug Events and Reports (RADAR) project." JAMA 293 (2005): 2131-40. [PMID: 15870417]
52 Product Information. Vumerity (diroximel fumarate). Alkermes, Inc, Cambridge, MA.
53 Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
54 Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
55 Product Information. Synribo (omacetaxine). Teva Pharmaceuticals USA, North Wales, PA.
56 Cohen J "Long-term efficacy and safety of terazosin alone and in combination with other antihypertensive agents." Am Heart J 122 (1991): 919-25. [PMID: 1678923]
57 Product Information. Alimta (pemetrexed). Lilly, Eli and Company, Indianapolis, IN.
58 Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
59 Product Information. Arcalyst (rilonacept). Regeneron Pharmaceuticals Inc, Tarrytown, NY.
60 Product Information. Cimzia (certolizumab). UCB Pharma Inc, Smyrna, GA.
61 Product Information. Orap Tablets (pimozide). Gate Pharmaceuticals, Sellersville, PA.
62 CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]
63 Antonelli D, Atar S, Freedberg NA, Rosenfeld T "Torsade de pointes in patients on chronic amiodarone treatment: contributing factors and drug interactions." Isr Med Assoc J 7 (2005): 163-5. [PMID: 15792261]